These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

962 related articles for article (PubMed ID: 26889021)

  • 1. Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox.
    Kaever T; Matho MH; Meng X; Crickard L; Schlossman A; Xiang Y; Crotty S; Peters B; Zajonc DM
    J Virol; 2016 May; 90(9):4334-4345. PubMed ID: 26889021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.
    Kaever T; Meng X; Matho MH; Schlossman A; Li S; Sela-Culang I; Ofran Y; Buller M; Crump RW; Parker S; Frazier A; Crotty S; Zajonc DM; Peters B; Xiang Y
    J Virol; 2014 Oct; 88(19):11339-55. PubMed ID: 25031354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species-Specific Conservation of Linear Antigenic Sites on Vaccinia Virus A27 Protein Homologs of Orthopoxviruses.
    Ahsendorf HP; Gan LL; Eltom KH; Abd El Wahed A; Hotop SK; Roper RL; Beutling U; Broenstrup M; Stahl-Hennig C; Hoelzle LE; Czerny CP
    Viruses; 2019 May; 11(6):. PubMed ID: 31146446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of Vaccinia Virus-Neutralizing Antibody from a Phage-Display Human-Antibody Library.
    Shin YW; Chang KH; Hong GW; Yeo SG; Jee Y; Kim JH; Oh MD; Cho DH; Kim SH
    J Microbiol Biotechnol; 2019 Apr; 29(4):651-657. PubMed ID: 30856707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
    He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
    J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of murine antibody responses to vaccinia virus envelope protein A14 reveals an immunodominant antigen lacking of effective neutralization targets.
    Meng X; Kaever T; Yan B; Traktman P; Zajonc DM; Peters B; Crotty S; Xiang Y
    Virology; 2018 May; 518():284-292. PubMed ID: 29558682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8.
    Matho MH; Schlossman A; Gilchuk IM; Miller G; Mikulski Z; Hupfer M; Wang J; Bitra A; Meng X; Xiang Y; Kaever T; Doukov T; Ley K; Crotty S; Peters B; Hsieh-Wilson LC; Crowe JE; Zajonc DM
    J Biol Chem; 2018 Jan; 293(1):390-401. PubMed ID: 29123031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody Recognition of Immunodominant Vaccinia Virus Envelope Proteins.
    Zajonc DM
    Subcell Biochem; 2017; 83():103-126. PubMed ID: 28271474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies.
    Xu C; Meng X; Yan B; Crotty S; Deng J; Xiang Y
    Virology; 2011 Sep; 418(1):67-73. PubMed ID: 21810533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine.
    Benhnia MR; Maybeno M; Blum D; Aguilar-Sino R; Matho M; Meng X; Head S; Felgner PL; Zajonc DM; Koriazova L; Kato S; Burton DR; Xiang Y; Crowe JE; Peters B; Crotty S
    J Virol; 2013 Feb; 87(3):1569-85. PubMed ID: 23152530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capturing the natural diversity of the human antibody response against vaccinia virus.
    Lantto J; Haahr Hansen M; Rasmussen SK; Steinaa L; Poulsen TR; Duggan J; Dennis M; Naylor I; Easterbrook L; Bregenholt S; Haurum J; Jensen A
    J Virol; 2011 Feb; 85(4):1820-33. PubMed ID: 21147924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein.
    Isaacs SN; Argyropoulos E; Sfyroera G; Mohammad S; Lambris JD
    J Virol; 2003 Aug; 77(15):8256-62. PubMed ID: 12857894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread.
    He Y; Wang Y; Struble EB; Zhang P; Chowdhury S; Reed JL; Kennedy M; Scott DE; Fisher RW
    Virol J; 2012 Sep; 9():217. PubMed ID: 23006741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax.
    Midgley CM; Putz MM; Weber JN; Smith GL
    J Gen Virol; 2008 Dec; 89(Pt 12):2992-2997. PubMed ID: 19008384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.
    Messer WB; Yount BL; Royal SR; de Alwis R; Widman DG; Smith SA; Crowe JE; Pfaff JM; Kahle KM; Doranz BJ; Ibarra KD; Harris E; de Silva AM; Baric RS
    J Virol; 2016 May; 90(10):5090-5097. PubMed ID: 26962223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and functional analysis of orthopoxvirus epitopes with neutralizing monoclonal antibodies.
    Czerny CP; Mahnel H
    J Gen Virol; 1990 Oct; 71 ( Pt 10)():2341-52. PubMed ID: 1700065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.
    Golden JW; Zaitseva M; Kapnick S; Fisher RW; Mikolajczyk MG; Ballantyne J; Golding H; Hooper JW
    Virol J; 2011 Sep; 8():441. PubMed ID: 21933385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.
    Fong RH; Banik SS; Mattia K; Barnes T; Tucker D; Liss N; Lu K; Selvarajah S; Srinivasan S; Mabila M; Miller A; Muench MO; Michault A; Rucker JB; Paes C; Simmons G; Kahle KM; Doranz BJ
    J Virol; 2014 Dec; 88(24):14364-79. PubMed ID: 25275138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine.
    Benhnia MR; McCausland MM; Su HP; Singh K; Hoffmann J; Davies DH; Felgner PL; Head S; Sette A; Garboczi DN; Crotty S
    J Virol; 2008 Apr; 82(7):3751-68. PubMed ID: 18234801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.